{"result": "(\"entity\"<|>UPTODATE INC.<|>ORGANIZATION<|>UpToDate Inc. is a medical resource providing clinical decision support and information for healthcare professionals.)\n##\n(\"entity\"<|>ELSEVIER<|>ORGANIZATION<|>Elsevier is a publishing company known for its medical textbooks and journals, including the Williams Textbook of Endocrinology.)\n##\n(\"entity\"<|>WALTHAM<|>GEO<|>Waltham is a city in Massachusetts, USA, where UpToDate Inc. is located.)\n##\n(\"entity\"<|>PHILADELPHIA<|>GEO<|>Philadelphia is a city in Pennsylvania, USA, known for being the location of Elsevier's publishing operations.)\n##\n(\"entity\"<|>PTHrP<|>EVENT<|>PTHrP (Parathyroid Hormone-related Peptide) is a protein associated with hypercalcemia in malignancy, acting similarly to parathyroid hormone.)\n##\n(\"entity\"<|>HYPERCALCEMIA<|>EVENT<|>Hypercalcemia is a condition characterized by an abnormally high level of calcium in the blood, often associated with various medical conditions including malignancies.)\n##\n(\"entity\"<|>HYPERPARATHYROIDISM<|>EVENT<|>Hyperparathyroidism is a condition where the parathyroid glands produce too much parathyroid hormone, leading to elevated calcium levels in the blood.)\n##\n(\"entity\"<|>GAMMAGRAFÍA CON SESTAMIBI<|>EVENT<|>Gammagrafía con sestamibi is a nuclear medicine test used to locate parathyroid adenomas.)\n##\n(\"entity\"<|>NODULOS TIROIDEOS<|>EVENT<|>Nódulos tiroideos are thyroid nodules that can complicate the diagnosis of hyperparathyroidism.)\n##\n(\"relationship\"<|>UPTODATE INC.<|>ELSEVIER<|>UpToDate Inc. and Elsevier are both involved in the publication of medical literature and resources for healthcare professionals<|>5)\n##\n(\"relationship\"<|>WALTHAM<|>UPTODATE INC.<|>Waltham is the location of UpToDate Inc., which is a significant organization in the medical publishing field<|>7)\n##\n(\"relationship\"<|>PHILADELPHIA<|>ELSEVIER<|>Philadelphia is the headquarters of Elsevier, a major publisher of medical textbooks and journals<|>7)\n##\n(\"relationship\"<|>PTHrP<|>HYPERCALCEMIA<|>PTHrP is a key factor in the development of hypercalcemia associated with malignancy<|>8)\n##\n(\"relationship\"<|>HYPERCALCEMIA<|>HYPERPARATHYROIDISM<|>Hypercalcemia can be a result of hyperparathyroidism, where excess parathyroid hormone leads to increased calcium levels<|>8)\n##\n(\"relationship\"<|>GAMMAGRAFÍA CON SESTAMIBI<|>HYPERPARATHYROIDISM<|>Gammagrafía con sestamibi is used to locate parathyroid adenomas in patients suspected of having hyperparathyroidism<|>6)\n##\n(\"relationship\"<|>NODULOS TIROIDEOS<|>HYPERPARATHYROIDISM<|>Nódulos tiroideos can complicate the diagnosis of hyperparathyroidism, making imaging tests more challenging<|>4)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ceso 6 de junio de 2019).\n        • Brown EM. Disorders of the calcium-sensing receptor: Familial hypocalciuric-hypercalcemia and autosomal dominant hypocalcemia.                 • Horwitz MJ. Hypercalcemia of malignancy: Mechanisms. Rosen CJ, ed. UptoDate. Waltham, MA: UpToDate Inc.\n          Rosen CJ, ed. UptoDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com (acceso 6 de junio de 2019).                                         https://www.uptodate.com (acceso 7 de junio de 2019).\n        • El-Hajj Fuleihan G, Silverberg SJ. Primary hyperparathyroidism: Diagnosis, differential diagnosis, and evaluation. Rosen CJ, ed. UptoDate.     • Melmed S, Polonsky KS, Reed Larsen P, Kronenberg HM. Williams Textbook of Endocrinology. 13.ª ed. Philadelphia: Elsevier; 2016.\n          Waltham, MA: UpToDate Inc. https://www.uptodate.com (acceso 6 de junio de 2019).\n        • Melmed S, Polonsky KS, Reed Larsen P, Kronenberg HM. Williams Textbook of Endocrinology. 13.ª ed. Philadelphia: Elsevier; 2016.\n\n\n\n                                                                                                                                                      6  Le envían a consulta una paciente de 55 años para valoración de hipercalcemia.\n        Respecto a la hipercalcemia asociada con PTHrP elevada, señale la respuesta                                                                      Como antecedente destaca un bocio multinodular eutiroideo, dado de alta del\n     5                                                                                                                                                   servicio hace años tras varias ecografías sin crecimiento nodular. Analítica actual:\n        falsa:                                                                                                                                           calcio, 11,8 mg/dl (8,5-10,4 mg/dl); fósforo, 2,1 mg/dl (2,4-4,9 mg/dl); PTH, 76 pg/ml\n        A. Es la causa más frecuente de hipercalcemia en pacientes con tumores sólidos no                                                                (10-55 pg/ml); vitamina D, 33 ng/ml (suficiencia mayor de 30 ng/ml); calciuria,\n            metastásicos.                                                                                                                                405 mg/24 h. No hay antecedentes familiares de hipercalcemia. Usted cree que\n        B. La PTH habitualmente se encuentra suprimida o muy baja.                                                                                       la paciente tiene un hiperparatiroidismo primario (HPP) y considera que tiene\n        C. El mecanismo de producción de hipercalcemia relacionada con PTHrP se debe al                                                                  criterios quirúrgicos. Antes de derivar a cirugía pide como prueba de imagen\n            aumento de resorción ósea y de la reabsorción renal de calcio.                                                                               localizadora una gammagrafía con sestamibi, pero el resultado es negativo.\n        D.  La PTHrP actúa habitualmente mediante la unión a un receptor diferente al de la PTH.                                                         Señale cuál de las siguientes afirmaciones es falsa:\n                                                                                                                                                         A. Una gammagrafía con sestamibi negativa no excluye el diagnóstico de HPP, puesto que\n        COMENTARIO                                                                                                                                           ocurre en el 12-25% de los pacientes.\n        Las primeras acciones identificadas de la                  PTHrP fueron acciones            pseudo-PTH       asocia-                             B. Los resultados del sestamibi pueden mejorarse si: 1) se combina con imágenes en tres\n        das a la hipercalcemia humoral del cáncer, que representa hasta el 80% de los pacien-                                                                dimensiones (Sestamibi-Single Photon Emision Computed Tomography: SPECT), 2) se\n        tes con hipercalcemia de malignidad. En esta entidad patológica, la PTHrP actúa como                                                                 realiza una gammagrafía tiroidea y se practica una sustracción de imágenes o 3)\n        hormona; el tumor la segrega al torrente sanguíneo y                       actúa en      el  hueso (aumenta la                                       se realiza una fusión con imágenes de TAC (MIBl-SPECT-TAC).\n        resorción ósea) y en el riñón (reabsorción del calcio) por lo que sube la concentración                                                          C. La ecografía es a menudo usada para localización, y presenta como ventaja una mayor\n        de calcio.                                                                                                                                           sensibilidad para localizar adenomas paratiroideos en pacientes con nódulos tiroideos.\n        En muchas acciones, la PTHrP actúa a través del receptor PTH/PTHrP que es el mismo                                                               D.  La no localización del adenoma mediante pruebas de imagen no es criterio para no\n        de la PTH e imita todas las acciones de los fragmentos amino-terminales de la PTH (opción                                                            indicar la intervención si cumple criterios quirúrgicos. En estos casos debe realizarse\n        D falsa: respuesta correcta). La concentración sanguínea de PTHrP es alta en la mayoría                                                              exploración bilateral por un cirujano con experiencia.\n\n\n\n376                                                                                                                                                                                                                                                                                377\n---\n                                                                                                                                                                            METABOLIS\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}